Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strong Diabetes Franchise Growth Highlights Solid Third Quarter For Merck

This article was originally published in The Pink Sheet Daily

Executive Summary

Three new product launches also were among the bright spots in a quarter in which the pharma posted net income of $342 million.

You may also be interested in...



Merck To Join Pfizer and Lilly At Top of DoJ Settlements Chart

Merck is set to reach the third largest settlement with the Department of Justice involving drug marketing practices.

Merck To Join Pfizer and Lilly At Top of DoJ Settlements Chart

Merck is set to reach the third largest settlement with the Department of Justice involving drug marketing practices.

U.S. Merck Looks For Developing Country Markets

Merck's second-quarter results demonstrate the risks and rewards of becoming less U.S.-centric. Emerging markets expansion and new product launches outside of the U.S. drove growth, but EU price cuts dampened revenues and profits.

Related Content

Topics

UsernamePublicRestriction

Register

PS071380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel